<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d353" origId="Etanercept"><sentence id="DrugDDI.d353.s0" origId="s0" text="Specific drug interaction studies have not been conducted with ENBREL?."><negationtags>&lt;xcope&gt;Specific drug interaction studies have &lt;cue&gt;not&lt;/cue&gt; been conducted &lt;/xcope&gt; with ENBREL?.</negationtags></sentence><sentence id="DrugDDI.d353.s1" origId="s1" text="However, it was observed that the pharmacokinetics of ENBREL? was unaltered by concomitant methotrexate in rheumatoid arthritis patients."><entity charOffset="91-103" id="DrugDDI.d353.s1.e0" origId="s1.p14" text="methotrexate" type="drug"/></sentence><sentence id="DrugDDI.d353.s2" origId="s2" text="In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL? and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL? alone (0%)."><entity charOffset="104-112" id="DrugDDI.d353.s2.e0" origId="s2.p25" text="anakinra" type="drug"/></sentence><sentence id="DrugDDI.d353.s3" origId="s3" text="Two percent of patients treated concurrently with ENBREL? and anakinra developed neutropenia (ANC   1 x 109/L)."><entity charOffset="62-70" id="DrugDDI.d353.s3.e0" origId="s3.p47" text="anakinra" type="drug"/><entity charOffset="94-110" id="DrugDDI.d353.s3.e1" origId="s3.p51" text="ANC   1 x 109/L" type="drug"/><pair e1="DrugDDI.d353.s3.e0" e2="DrugDDI.d353.s3.e1" id="DrugDDI.d353.s3.p0" interaction="false"/></sentence><sentence id="DrugDDI.d353.s4" origId="s4" text="Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone."><entity charOffset="66-79" id="DrugDDI.d353.s4.e0" origId="s4.p58" text="sulfasalazine" type="drug"/><entity charOffset="90-96" id="DrugDDI.d353.s4.e1" origId="s4.p59" text="ENBREL" type="drug"/><entity charOffset="216-222" id="DrugDDI.d353.s4.e2" origId="s4.p75" text="ENBREL" type="drug"/><entity charOffset="229-242" id="DrugDDI.d353.s4.e3" origId="s4.p77" text="sulfasalazine" type="drug"/><pair e1="DrugDDI.d353.s4.e0" e2="DrugDDI.d353.s4.e1" id="DrugDDI.d353.s4.p0" interaction="true"/><pair e1="DrugDDI.d353.s4.e0" e2="DrugDDI.d353.s4.e2" id="DrugDDI.d353.s4.p1" interaction="false"/><pair e1="DrugDDI.d353.s4.e0" e2="DrugDDI.d353.s4.e3" id="DrugDDI.d353.s4.p2" interaction="false"/><pair e1="DrugDDI.d353.s4.e1" e2="DrugDDI.d353.s4.e2" id="DrugDDI.d353.s4.p3" interaction="false"/><pair e1="DrugDDI.d353.s4.e1" e2="DrugDDI.d353.s4.e3" id="DrugDDI.d353.s4.p4" interaction="false"/><pair e1="DrugDDI.d353.s4.e2" e2="DrugDDI.d353.s4.e3" id="DrugDDI.d353.s4.p5" interaction="false"/></sentence><sentence id="DrugDDI.d353.s5" origId="s5" text="The clinical significance of this observation is unknown."/></document>